ArticleInfection and drug resistance2021
CTX-M-15 Positive
Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Systematic review of multidrug-resistantFrontiers in microbiology · 2025Pooled it
- Evolution of Antimicrobial Resistance in Neonatal Sepsis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic Epidemiology of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern Africa.Antibiotics (Basel, Switzerland) · 2026Review
- Genetic diversity of ESBL-producingBioinformation · 2026Article
- Risk factors associated with extended spectrum beta lactamaseAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Pathogen Profiles and Antimicrobial Resistance Patterns of Neonatal Sepsis in the Gulf Cooperation Council: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producingFrontiers in antibiotics · 2023Review
- Successful Control of an Outbreak by Phenotypically Identified Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Extended Spectrum- and Carbapenemase-Based β-Lactam Resistance in the Arabian Peninsula-A Descriptive Review of Recent Years.Antibiotics (Basel, Switzerland) · 2022Review
- Evidence of Antimicrobial Resistance from Maternity Units and Labor Rooms: A Water, Sanitation, and Hygiene (WASH) Study from Gujarat, India.Healthcare (Basel, Switzerland) · 2022Article
- Emergence ofInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to retrospectively characterize
methodsAntibiotic susceptibility patterns, molecular characterization for antibiotic-resistant genes (
resultsA total of 24
conclusionThis is the first report of CTX-M-15-positive, ESBL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.